Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,303 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High blood pressure treatment Clear all
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Urban Zen Integrative Therapy for Persons With Pulmonary Hypertension

NCT03194438
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Disease
Interventions
Urban Zen Integrative Therapy (UZIT)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 7, 2026, 1:32 AM EDT
Terminated Not applicable Interventional

Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

NCT01952743
View directory record Official record
Conditions
Atrial Fibrillation, Hypertension
Interventions
AF ablation with Renal Denervation, AF ablation alone
Procedure
Lead sponsor
Siva Mulpuru
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 7, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study

NCT07363343
View directory record Official record
Conditions
Hypertension, Postpartum Preeclampsia
Interventions
Nifedipine and Enalapril, Nifedipine and Labetalol
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial

NCT03638908
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Fluoxetine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 7, 2026, 1:32 AM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension

NCT00457626
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Hackensack, New Jersey • Philadelphia, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 7, 2026, 1:32 AM EDT
Completed No phase listed Observational

Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant

NCT00510315
View directory record Official record
Conditions
Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
Questionnaires, Laboratory tests, Abdominal MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Diuretic Comparison Project

NCT02185417
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
20,723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 7, 2026, 1:32 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

NCT00034307
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sitaxsentan sodium
Drug
Lead sponsor
ICOS-Texas Biotechnology
Industry
Eligibility
16 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Working With Veterans Organizations to Improve Blood Pressure

NCT00571038
View directory record Official record
Conditions
Hypertension
Interventions
Peer Led, Seminar
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

NCT03617458
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
Metformin, Placebo, mHealth Intervention, Usual Care
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashvile, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

NCT03945643
View directory record Official record
Conditions
Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 7, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension

NCT00547300
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol ER, Nebivolol
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 7, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Repeated Far Infrared Sauna Bathing in Adults With Obesity

NCT07158047
View directory record Official record
Conditions
Obesity (Disorder)
Interventions
Heat therapy
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 7, 2026, 1:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

iControl Chronic Kidney Disease

NCT03951363
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
interactive Obesity Treatment Approach (iOTA)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 7, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT05347147
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Presendin, Placebo
Drug
Lead sponsor
Invex Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study

NCT02591628
View directory record Official record
Conditions
Hypertension
Interventions
HCTZ prescription conversion to chlorthalidone
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
2,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Bloomington, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 7, 2026, 1:32 AM EDT
Recruiting Phase 2 Interventional

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

NCT07238400
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone 100 mg daily, Chlorthalidone 25 mg daily, Potassium Placebo, Potassium Chloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 7, 2026, 1:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy

NCT00329511
View directory record Official record
Conditions
Hypertension
Interventions
methyldopa vs. clonidine, clonidine patch
Drug
Lead sponsor
Afshan B. Hameed, M.D.
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 7, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Effects of Use of a Connected Pillbox On Medication Adherence

NCT02593032
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions
Pre-filled trays
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 7, 2026, 1:32 AM EDT